Vitamin D receptor FokI polymorphism and the risks of colorectal cancer, inflammatory bowel disease, and colorectal adenoma

被引:0
|
作者
Young Ae Cho
Jeonghee Lee
Jae Hwan Oh
Hee Jin Chang
Dae Kyung Sohn
Aesun Shin
Jeongseon Kim
机构
[1] National Cancer Center,Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy
[2] National Cancer Center,Center for Colorectal Cancer, National Cancer Center Hospital
[3] Seoul National University College of Medicine,Department of Preventive Medicine
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Based on an inverse association between vitamin D levels and the risks of colorectal diseases, a functional start codon polymorphism in the vitamin D receptor (VDR) gene is speculated to affect the risks for these diseases. To validate this hypothesis, we first conducted a case-control study of 695 colorectal cancer patients and 1,397 controls. The association of VDR FokI polymorphism with colorectal cancer risk was analyzed using a logistic regression model. In the present case-control study, compared to the F allele, the f allele seemed to be associated with lower risks of colon cancer and advanced colorectal cancer. Additionally, a meta-analysis of 27 studies was conducted to combine findings from previous studies investigating the association of FokI polymorphism with colorectal disease using a random effects model. In the present meta-analysis, the f allele was positively associated with the risk of inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. However, this allele was inversely associated with colon cancer and was not associated with the risk of rectal cancer or colorectal adenoma. In conclusion, the findings from this study imply that the role of VDR FokI polymorphism may differ based on the type and severity of colorectal disease.
引用
收藏
相关论文
共 50 条
  • [21] FokI and TakI vitamin D receptor polymorphism in patients with prostate cancer
    Kwiatkowski, R.
    Braczkowski, R.
    Danikiewicz, A.
    Braczkowska, B.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S235 - S235
  • [22] Chemoprevention of colorectal cancer in inflammatory bowel disease
    Butterworth, J. R.
    DIGESTIVE AND LIVER DISEASE, 2009, 41 (05) : 338 - 339
  • [23] Colorectal cancer and dysplasia in inflammatory bowel disease
    Zisman, Timothy L.
    Rubin, David T.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (17) : 2662 - 2669
  • [24] Interval Colorectal Cancer in Inflammatory Bowel Disease
    Da Cunha, Teresa
    Vaziri, Haleh
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2024, 58 (01) : 1 - 11
  • [25] Chemoprevention of colorectal cancer in inflammatory bowel disease
    Subramanian, Venkataraman
    Logan, Richard F.
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2011, 25 (4-5) : 593 - 606
  • [26] Chemoprevention of colorectal cancer in inflammatory bowel disease
    Ehrlich, Adam C.
    Patel, Shyam
    Meillier, Andrew
    Rothstein, Robin D.
    Friedenberg, Frank K.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (03) : 247 - 255
  • [27] Chemoprevention of colorectal cancer in inflammatory bowel disease
    Munkholm, P
    IBD AND SALICYLATES - 5, 2001, 24 (01): : 51 - 57
  • [28] Colorectal cancer in idiopathic inflammatory bowel disease
    Harpaz, N
    Talbot, IC
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 1996, 13 (04) : 339 - 357
  • [29] Colorectal cancer and dysplasia in inflammatory bowel disease
    Timothy L Zisman
    David T Rubin
    World Journal of Gastroenterology, 2008, (17) : 2662 - 2669
  • [30] Incidence of colorectal cancer in inflammatory bowel disease
    Liu, Liyan
    Velayos, Fernando
    Allison, James
    Terdiman, Jonathan
    Lewis, James
    Hutfless, Susan
    Herrinton, Lisa
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S442 - S442